Lysosomal Movement and Anabolic Resistance

Sarcopenia Clinical Trial

Official title:

Defining the Role of Lysosomal Movement in Age-associated Anabolic Resistance in Human Skeletal Muscle

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03032757
• Other study ID #: RG_16-200
• Status: Recruiting
• Phase: N/A
• First received: January 19, 2017
• Last updated: October 24, 2017
• Start date: May 12, 2017
• Est. completion date: August 30, 2018

Study information

• Verified date: October 2017
• Source: University of Birmingham
• Contact: William Apro, Ph.D.
• Phone: 01214142875
• Email: w.apro[@]bham.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Age-associated loss of muscle mass, termed sarcopenia, is strongly associated with functional impairment and physical disability in the elderly. Maintenance or growth of muscle mass is mainly driven by increased muscle protein synthesis (i.e. the generation of new muscle protein) in response to exercise and feeding. However, several investigations have shown that elderly individuals have a blunted protein synthetic response following protein intake. This inability of the elderly to properly respond to growth stimuli has been termed anabolic resistance and plays a significant role in the development of sarcopenia. However, the precise mechanisms underpinning anabolic resistance are unknown.

It is well established that muscle protein synthesis at the molecular level is regulated by a cellular protein complex called mTORC1. When exposed to a growth stimulus, mTORC1 has been shown to associate with lysosomes, i.e. the intracellular organelles responsible for the breakdown of cellular proteins, and subsequently moving towards the cell periphery.

This movement of lysosome-associated mTORC1 within the cell is believed to be vital for the activation of protein synthesis, as inhibition of lysosomal movement blunts mTORC1 activation in response to amino acids. Thus, dysregulation of lysosomal movement in ageing muscle may represent an underlying mechanism in the development of anabolic resistance. However, this area of research is unexplored in the context of human skeletal muscle. The investigators hypothesize that dysregulation of lysosomal movement plays a central role in the development of age-associated skeletal muscle anabolic resistance.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 26
• Est. completion date: August 30, 2018
• Est. primary completion date: August 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Be a non-smoking male within the specified age range for each group (young; 18-35 yrs, old; 65-75 yrs)

Have a BMI (body mass index, body weight/height in m2) between 18 and 25 kg/m2, which is considered a normal body mass index.

Be in good general health: no cardiovascular diseases or metabolic diseases.

Exclusion Criteria:

Health problems such as: heart disease , metabolic disease such as phenylketonuria, rheumatoid arthritis, uncontrolled hypertension, poor lung function, or any health condition that might put the participant at risk when participating in this study.

Generalized neuromuscular disease (such as Parkinson's disease or motorneuron disease).

Involvement in regular structured resistance exercise training at the time of the study.

Consumption of any analgesic drugs, anti-inflammatory drugs, or medication that is known to affect protein metabolism (beta-blockers, corticosteroids, NSAIDs).

Participants who have undergone muscle biopsy testing or isotope infusion procedures within the last 5 years.

Allergic to lidocaine

Related Conditions & MeSH terms

• Sarcopenia

Intervention

Dietary Supplement:
• Essential amino acids
240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.

Locations

Country	Name	City	State
United Kingdom	School of Sport, Exercise and Rehabilitation Sciences at University of Birmingham	Birmingham	West Midlands

Sponsors (1)

Lead Sponsor	Collaborator
University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lysosomal movement	Changes in intracellular localization of lysosomes will be measured via immunofluorescence	~360 minutes
Secondary	Lysosomal movement in isolated muscle cells	Changes in intracellular localization of lysosomes will be measured via immunofluorescence	~30 minutes